PIPGEN - PhD Project 5: Biomarkers of chronically hyperactivated PI3Kδ in patients with APDS.
Research · Amsterdam UMC, locatie VUmc > Netherlands
RESEARCH PROFILE: First Stage Researcher (R1)
APPLICATION DEADLINE: 27 June 2021
EU RESEARCH FRAMEWORK PROGRAME: HORIZON 2020
MARIE SKOLODOWSKA CURIE GRANT AGREEMENT NUMBER: 955534
 First Stage Researcher (R1) PhD candidate or equivalent. Early stage researcher with less than 4 years FTE research experience.
PhD Project details
Activated PI3 kinase Delta Syndrome (APDS) is a rare disease previously discovered by the group of Prof Sergey Nejentsev (Angulo et al, Science, 2013). It is caused by mutations that increase PI3 kinase δ activity. APDS patients are immunodeficient and have high risks of bronchiectasis, autoimmune manifestations and lymphomas, suggesting that hyperactivated PI3 kinase δ contributes to the pathogenesis of these disorders. ESR5 will use advanced cell and molecular techniques to characterise immunological consequences of chronically hyperactivated PI3 kinase δ in APDS as well as related common disorders.
Host: Amstersdam UMC (location VUmc), NL.
Supervisor: Prof Sergey Nejentsev.
Doctoral programme: Vrije University of Amsterdam (4 Years PhD Program).
Envisioned secondments: University of Cambridge, Inserm.